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Aims: The diagnosis of autoimmune pancreatitis (AIP) and immunoglobulin subclass 4 (IgG4)-associated
cholangitis (IAC) is based on imaging studies, serology, histology and a response to steroid therapy. The
major serological finding is an elevation of the serum IgG4 concentration. Previous studies have shown
that its sensitivity is about 70% and its specificity exceeds 90% at a cut-off of 140 mg/dl in selected
patient populations. The aim of the present study was to assess the performance of serum IgG4 as a
diagnostic parameter in an unselected liver and pancreas clinic population.
Methods and results: IgG4 was prospectively determined in 1412 patients and clinical diagnoses were
recorded from a review of patient charts. The prevalence of AIP or IAC in the entire cohort was 1.1%
(n = 15). The sensitivity of IgG4 for the diagnosis of AIP and IAC was 80% and the specificity was 86%
at a cut-off value of 135 mg/dl. The positive predictive value and the negative predictive value were 6%
and 99.7%, respectively. The most common differential diagnosis in patients with elevated IgG4 was liver
cirrhosis.
Conclusion: IgG4 has a reasonable sensitivity and specificity in a liver and pancreas clinic
population, where liver cirrhosis appears to be the most frequent differential diagnosis for elevated IgG4
concentrations.
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Introduction
Immunoglobulin subclass 4 (IgG4)-associated diseases are an
increasingly recognized group of autoimmune diseases,1,2
which are characterized by sclerosis and lymphoplasmocytic
infiltration of affected organs with IgG4-positive cells.2–5 The
disease can affect the pancreas, biliary tract, salivary glands,
retroperitoneum, lymph nodes, kidney, lungs or the prostate.6,7
In the gastrointestinal tract, autoimmune pancreatitis (AIP) and
IgG4-associated cholangitis (IAC) are considered the most
common manifestations.8
The prevalence of AIP ranges from 4% to 8% among patients
with pancreatitis in different study cohorts.9 Common differential
diagnoses of AIP and IAC include chronic pancreatitis, pancreatic
cancer and primary sclerosing cholangitis.1,10,11 Male predomi-
nance and a mean age of 60  10 years were consistently
reported.5,6,12,13 Clinicopathological and radiological features
include jaundice, abdominal pain, and diabetes mellitus, extra and
The preliminary results of this study were presented as a poster at the
AASLD (American Association for the Study of Liver Diseases) liver meeting
2010 in Boston.
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intrahepatic biliary strictures, pancreatic duct encasement and a
sausage shape of the pancreas on abdominal magnetic resonance
imaging (MRI) or computed tomography (CT).1,5,6,13
Studies on IgG4-related diseases were predominantly carried
out in Asian countries,14–16 the United States of America5 and
Europe,9,17 where different diagnostic criteria for AIP have been
proposed by several societies. The Japanese and Korean criteria
were established in 2006 and 2007, respectively.15,16 The HISORt
criteria (Histology, Imaging, Serology, Other organ involvement,
Response to therapy) were proposed by Chari et al. in 2006.5
The typical histological finding of IgG4-related diseases is infil-
tration of affected organs with IgG4-positive plasma cells.5,15,16
Imaging studies in patients with IAC or AIP show irregular nar-
rowing of the bile ducts or the pancreatic duct by endoscopic
retrograde cholangiopancreaticography (ERCP), and enlargement
of affected organs or pseudotumour formation. Elevated serum
IgG4 and autoantibodies (ANA and RF) are commonly found in
serological studies.1,5,9,15,16 More specific antibodies directed
against carbonic anhydrase II, SPINK1 or trypsinogen have been
identified.18 The performance of total IgG4 serum concentrations
for the diagnosis of IgG4-related diseases has been evaluated in
different studies. A cut-off for IgG4 elevation was suggested at
135 mg/dl by Hamano et al. in 2001 with a sensitivity of 95%
and a specificity of 97%.4 The Mayo Clinic group reported a
specificity and a sensitivity of 93% and 76%, respectively, at a
cut-off level of >140 mg/dl. In patients with IgG4 concentrations
>280 mg/dl, a sensitivity of 53% and a specificity of 99% was
found.5 Based on these findings, the IgG4 serum concentration has
been proposed as a non-invasive parameter for the diagnosis of
IgG4-related disease and is included in the HISORt criteria.
The aim of the present study was to evaluate the sensitivity and
specificity of a serum IgG4 concentration in an unselected liver
and pancreas clinic population.
Patients and methods
From January 2009 to May 2010, serum immunoglobulin sub-
classes were prospectively determined in all patients referred to
the unit of gastroenterology and hepatology at the Medical Uni-
versity Innsbruck, Austria. To record clinical diagnoses, patients’
charts were carefully reviewed and a diagnosis of AIP and AIC was
made according to the HISORt and ASIAN criteria. IgG4 concen-
trations were determined in patients’ sera using the immunoglo-
bulin subclass assay from Siemens N IGG4 (formerly Dade
Behring, Marburg, Germany) on a Behring Nephelometryplat-
form (BN II). The interassay coefficients of variation were 3.7% at
0.195 g/l, 2.4% at 0.507 g/l and 3.5% at 0.729 g/l, respectively.
Statistical analysis
Results are shown as absolute numbers and medians (with range).
Analysis of variables with a non-normal distribution was carried
out using Mann–Whitney U-tests and means of normally distrib-
uted variables were compared with t-tests. Exact P-values for fre-
quency tables were calculated using the chi-square test and
association of variables was assessed by Pearson’s correlation. A
two-sided P-value of less than 0.05 was considered statistically
significant. The diagnostic performance of IgG4 was calculated by
receiver-operating characteristic (ROC) analyses with the area-
under-the-curve (AUC) statistic and a 95% confidence interval
(CI). The statistical analysis of the data was performed in SPSS
version 18.0 (SPSS, Chicago, IL, USA).
Results
The diagnostic performance of IgG4 was determined in 1412 con-
secutive patients referred to our unit from January 2009 to May
2010. Baseline demographic characteristics are shown in Table 1.
A diagnosis of pancreatitis or cholangitis was made in 192 patients
(13%). Male gender was predominant in both diseases and
median age did not significantly differ between these two groups.
The median IgG4 concentration in patients with pancreatitis
was 45.7 mg/dl (range: 1.8–1330 mg/dl), in patients with cholan-
gitis 70.0 mg/dl (range: 6.6–669.0 mg/dl) and 47.5 mg/dl (range:
0.2–1230.0 mg/dl) in the remaining patient cohort. These differ-
ences did not reach statistical significance. An IgG4 concentration
of 135 mg/dl was found in 210 of 1412 patients (14.9%).
Review of patient charts in the entire cohort identified 22
patients with the clinical diagnosis AIP or IAC. Of these, 15 ful-
filled HISORt and Asian criteria for the diagnosis of IgG4-related
diseases. A median IgG4 concentration in patients with IAC
according to HISORt was 240 mg/dl (range: 101–669) and
94 mg/dl (3.5–1330) in patients with AIP compared with
47.1 mg/dl in the remaining cohort (P < 0.001).
The prevalence of AIP and/or IACwas 1.1% in the entire cohort
(15 of 1412) and 7.8% in the subgroup of 192 patients with
pancreatitis or cholangitis. In all, 80% of patients with AIP or IAC
(12 of 15) had an IgG4 concentration above 135 mg/dl as com-
pared with 14% of patients without AIP or IAC (198 of 1397).
This results in a positive predictive value of 5.7%.
At a cut-off of 135 mg/dl, the sensitivity of IgG4 for the diag-
nosis of AIP or IAC was 80% (95% CI: 55% to 93%) and the
specificity was 86% [95% confidence interval (CI): 84% to 88%;
Table 2]. The area under the ROC curve was 0.837 (95% CI: 0.713
to 0.960; Fig. 1) and the optimal cut-off in our patient cohort was
145 mg/dl with a sensitivity of 80% and a specificity of 88%.
To identify potential causes of elevated serum IgG4 concentra-
tions, the main diagnoses were recorded in all 210 patients with a
Table 1 Gender distribution and age in the entire patient cohort and
in the subgroups of patients with pancreatitis and cholangitis
n (females) Median age
(range) years
All patients 1412 (595) 54 (17–99)
Pancreatitis 142 (46) 54 (17–99)
Cholangitis 50 (13) 59 (25–81)
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serum IgG4  135 mg/dl (Table 3). Cirrhosis was the most fre-
quent diagnosis and present in 35% of patients with an IgG4
serum concentration  135 mg/dl. Further diagnoses commonly
associated with IgG4  135 mg/dl were fatty liver disease (17%),
viral/toxic hepatitis (11%), haemochromatosis (4%), other
autoimmune diseases (3%) and other gastrointestinal disorders
including malignancies (14%). Median IgG4 concentrations did
not differ significantly between these groups.
An increased serum IgG4 concentration in liver cirrhosis
patients could be attributed to hypergammaglobulinaemia which
is a common finding in patients with portal hypertension. Corre-
lation analysis showed that IgG4 was weakly correlated with total
immunoglobulin in the entire cohort (r = 0.4, P < 0.001).
However, the area under the ROC curve of the IgG4/total IgG ratio
(AUC: 0.838; 95% CI: 0.713 to 0.962) was not different from that
of IgG4, indicating that the diagnostic performance of IgG4 cannot
be improved by including total IgG.
Discussion
Autoimmune pancreatitis and IAC are typically associated with
elevated serum IgG4 concentrations, where its positive and nega-
tive predictive values in a selected patient population are 36% and
99% at a threshold of 140 mg/dl.10 A general gastroenterology and
hepatology clinic population was investigated in the present study
where a reasonable sensitivity (80%) and specificity (86%) of IgG4
was found (Table 2).
A surprising result of the present study is the frequent increase
in serum IgG4 in patients with other underlying diseases, espe-
cially in patients with end-stage liver disease. The high number of
false-positive results translates to a positive predictive value of
only 6% for a cut-off of 135 mg/dl. Whether liver cirrhosis is a
consequence of IAC in these patients or increased serum IgG4
concentrations result from impaired metabolic function has to be
established. Nevertheless, liver cirrhosis should be considered as a
differential diagnosis in patients with unexplained IgG4 elevation.
The optimal cut-off was 145 mg/dl in the present study, which
is close to the cut-off of 140 mg/dl suggested in the HISORt cri-
teria.5 The varying cut-offs suggested by different groups may be a
result of different assays used for measurement of serum IgG4:
Nephelometric assays were used in the present study and by the
Mayo group,5 whereas an enzyme-linked immunosorbent assay
and a single radial immunodiffusion assay was used by Hamano
et al.4 As previously shown, even at a threshold of >200 mg/dl,
pancreatic cancer or cholangiocarcinoma cannot be excluded10
which illustrates the necessity for a biopsy to confirm the
diagnosis.
The negative predictive value of IgG4 was 99% in a previous
study10 which was confirmed in our study. An important differ-
ential diagnosis in patients with suspected AIP and negative IgG4
is type II AIP, whose diagnosis relies on the histological finding of
granulocytic epithelial lesions and narrowing of the pancreatic
duct.18 Findings from non-invasive tests that are indicative of type
II AIP are the positivity for ANA, SMA or more specific autoan-
Table 2 Diagnostic performance of serum IgG4 concentration for the
diagnosis of AIP or IAC at a cut off of 135 mg/dl
95% confidence
interval
Sensitivity 80% 55%–93%
Specificity 86% 84%–88%
Positive likelihood ratio 5.6 4.3–7.5
Negative likelihood ratio 0.2 0.1–0.6
Diagnostic odds ratio 24.2 6.8–86.6
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Figure 1 Receiver-operating curve (ROC) curve analysis of serum
immunoglobulin subclass 4 (IgG4) at a cut-off of 135 mg/dl for the
diagnosis of autoimmune pancreatitis (AIP) and IgG4-associated
cholangitis or IAC
Table 3 Diagnoses of patients with serum immunoglobulin subclass
4 (IgG4) concentrations  135 mg/dl (n = 210)
Diagnosis n (%)
Liver cirrhosis with or without HCC 72 (35%)
Steatosis 35 (17%)
Viral/toxic hepatitis 24 (11%)
Cholangitis including IAC 21 (10%)
Pancreatitis including AIP 8 (4%)
Hemochromatosis 8 (4%)
Other autoimmune diseases 6 (3%)
Cholecystitis/cholecystolithiasis 3 (1%)
Budd Chiari syndrome 2 (1%)
Other gastrointestinal diseases/malignancies 30 (14%)
HCC, hepatocellular carcinoma; IAC, IgG4-associated cholangitis; AIP,
autoimmune pancreatitis.
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tibodies directed against carbonic anhydrase II, SPINK1 or trypsi-
nogen.18 Another condition where a false-negative IgG4 test result
could be expected is previous treatment with steroids.19
In conclusion, AIP and IAC are emerging entities, whose diag-
nosis relies on clinical, radiological, biochemical and histological
criteria. In clinical practice, malignant diseases of the biliary tree
and pancreas are important differential diagnoses. Clear diagnos-
tic criteria, ideally based on non-invasive tests, are required to
avoid unnecessary surgery and to discriminate inflammatory
from neoplastic diseases. Practical limitations of HISORt criteria
are that invasive procedures are required to obtain histology and
that the response to steroids can only be assessed after the pre-
sumed diagnosis has been made.
The present study confirms that the proposed threshold for
IgG4 is in the range of 135 mg/dl and shows that in spite of its
excellent negative predictive value, its positive predictive value
renders it insufficient to be used as an isolated parameter. Further-
more, serum IgG4 is not suited as a first-line screening test, owing
to the low prevalence of IgG4-related diseases and the high rate of
false-positive results. Particularly liver cirrhosis is an important
differential diagnosis and commonly associated with elevated
IgG4.
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